Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Benitec Biopharma (BNTC) Interest & Investment Income (2019 - 2025)

Historic Interest & Investment Income for Benitec Biopharma (BNTC) over the last 7 years, with Q2 2025 value amounting to $1.0 million.

  • Benitec Biopharma's Interest & Investment Income rose 1260.87% to $1.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was $3.3 million, marking a year-over-year increase of 26349.56%. This contributed to the annual value of $3.3 million for FY2025, which is 26349.56% up from last year.
  • As of Q2 2025, Benitec Biopharma's Interest & Investment Income stood at $1.0 million, which was up 1260.87% from $823000.0 recorded in Q1 2025.
  • In the past 5 years, Benitec Biopharma's Interest & Investment Income ranged from a high of $1.0 million in Q2 2025 and a low of -$11000.0 during Q4 2021
  • For the 5-year period, Benitec Biopharma's Interest & Investment Income averaged around $229000.0, with its median value being -$5000.0 (2023).
  • Its Interest & Investment Income has fluctuated over the past 5 years, first crashed by 90000.0% in 2022, then surged by 2067500.0% in 2025.
  • Quarter analysis of 5 years shows Benitec Biopharma's Interest & Investment Income stood at -$11000.0 in 2021, then rose by 18.18% to -$9000.0 in 2022, then surged by 33.33% to -$6000.0 in 2023, then surged by 13816.67% to $823000.0 in 2024, then rose by 25.88% to $1.0 million in 2025.
  • Its Interest & Investment Income was $1.0 million in Q2 2025, compared to $823000.0 in Q1 2025 and $823000.0 in Q4 2024.